Hansoh Pharmaceutical Group's (HKG:3692) HS-20093 for injection obtained China's National Medical Products Administration's (NMPA) approval to be added as a breakthrough-therapy-designated drug for the treatment of patients with osteosarcoma, a type of bone cancer, a Tuesday bourse filing said.
The Chinese regulator approved the drug for the treatment of patients who have progressed on at least two prior lines of therapy.
HS-20093, also known as GSK5764227, is a B7-H3-targeted antibody-drug conjugate that is being developed in multiple clinical studies of small-cell lung cancer, head and neck cancers, and other solid tumors.
The injection has also been granted breakthrough therapy designation by NMPA previously for lung cancer and from the US Food and Drug Administration for the treatment of relapsed or refractory extensive-stage small-cell lung cancer, ES-SCLC.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。